The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
Zacks.com on MSN
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...
Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and ...
Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.
Population aging is reshaping the landscape of respiratory disease, with COPD, idiopathic pulmonary fibrosis, bronchiectasis, ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
The peptide known as BPC‑157 (pentadecapeptide BPC-157) has garnered increasing attention across research domains ...
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
FRIDAY, Jan. 23, 2026 (HealthDay News) — Brain tumors are abnormal growths of cells in or around the brain. They can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results